At 5-year follow-up , rates of major adverse cardiac events were similar in patients treated with both types of stents ( zotarolimus-eluting stents 197/1162 [ 17.0 % ] vs sirolimus-eluting stents 182/1170 [ 15.6 % ] ; odds ratio [ OR ] 1.10 , 95 % CI 0.88-1 .37 ; p = 0.40 ) .